Results 341 to 350 of about 1,198,051 (418)
Some of the next articles are maybe not open access.

Platelet-activating factor receptor

Prostaglandins & Other Lipid Mediators, 2002
Platelet-activating factor (PAF, 1-O-alkyl-2-acetyl-sn-glycero-3-phosphocholine) is a biologically active phospholipid mediator. Although PAF was named for its potential to induce platelet aggregation, intense investigations have elucidated potent biological actions of PAF in a broad range of cell types and tissues.
Takahide Nagase   +2 more
openaire   +5 more sources

Radioimmunoassay for platelet‐activating factor

Lipids, 1991
AbstractA radioimmunoassay (RIA) for measurement of platelet‐activating factor (PAF) was developed. At a final antiserum dilution of 1∶640, the lowest detection limit of PAF was 0.1 pmol (50 pg). The standard curve obtained was suitable for measurement of PAF in amounts ranging from 0.1 pmol to 30 pmol. The antiserum showed high specificity.
Ken Karasawa   +5 more
openaire   +3 more sources

Platelet-Activating Factor

2007
Platelet-activating factor (PAF) is a potent mediator that occurs at very low concentrations in cells and tissues. Accurate quantitation of PAF has always been difficult because of the physicochemical properties of PAF and its structural similarity to several much more abundant phospholipids.
Robert L. Wykle   +2 more
openaire   +3 more sources

Necrotizing enterocolitis: pathophysiology, platelet-activating factor, and probiotics.

Seminars in Pediatric Surgery, 2013
Although smaller and younger preterm neonates can now survive long term due to advances in neonatal medicine, necrotizing enterocolitis (NEC) continues to plague the clinicians caring for these tiny patients.
Brandy L. Frost, M. Caplan
semanticscholar   +1 more source

Sensory and signaling mechanisms of bradykinin, eicosanoids, platelet-activating factor, and nitric oxide in peripheral nociceptors.

Physiological Reviews, 2012
Peripheral mediators can contribute to the development and maintenance of inflammatory and neuropathic pain and its concomitants (hyperalgesia and allodynia) via two mechanisms. Activation or excitation by these substances of nociceptive nerve endings or
G. Pethő, P. Reeh
semanticscholar   +1 more source

Platelet-Activating Factor

Hospital Practice, 1983
Our ability to chemically characterize and synthesize this autacoid of allergy and inflammation has given us a unique opportunity to study these important molecules in a highly disciplined fashion. It has also opened the door to a vista of research approaches to define PAF's normal physiologic role as well as its actions as an immunopathologic mediator.
openaire   +3 more sources

Platelet-Activating Factor and Angiogenesis

1996
Platelet-activating factor (PAF) is a phospholipid autacoid with a spectrum of diverse and potent biological properties relevant for the development of inflammatory reaction and septic shock1. Recently, PAF has been also implicated in the embryogenesis and cell differentiation2,3. Researchers believe that PAF is a mediator of cell to cell communication
CAMUSSI, Giovanni   +4 more
openaire   +4 more sources

Platelet-activating factor antagonists

Clinical Reviews in Allergy, 1995
The great number of PAF antagonists reviewed in this article clearly shows the tremendous effort made in the last 20 yr to explore the complex biological background of the mechanism of action of PAF and the potential clinical benefit of its antagonists. It is obvious that now highly potent, long-acting, and perorally applicable PAF-receptor antagonists
Pierre Braquet, Matyas Koltai
openaire   +5 more sources

Platelet-Activating Factor

Scandinavian Journal of Gastroenterology, 1996
Platelet-activating factor (PAF) is a proinflammatory lipid. It has been strongly implicated in the regulation of pancreatic exocrine secretion and in the local and systemic events which occur in acute pancreatitis. PAF antagonists, when given as pretreatment, ameliorate the severity of experimental acute pancreatitis by reducing serum amylase ...
openaire   +2 more sources

Platelet-activating factor and asthma

Journal of Allergy and Clinical Immunology, 1988
anaphylaxis. And if you research into the 1920s) there a very useful treatment in blocking both thrombocyare articles, particularly in the German literature, that topenia and some of the features of anaphylaxis. The report thrombocytopenia as being a feature of clinical first article (1924) stated that heparin totally prevents asthma.
openaire   +5 more sources

Home - About - Disclaimer - Privacy